Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
1.020
-0.070 (-6.42%)
Dec 20, 2024, 4:00 PM EST - Market closed
Context Therapeutics Employees
Context Therapeutics had 5 employees as of December 31, 2023. The number of employees decreased by 4 or -44.44% compared to the previous year.
Employees
5
Change (1Y)
-4
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$6,030,416
Market Cap
76.50M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5 | -4 | -44.44% |
| Dec 31, 2022 | 9 | 8 | 800.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| So-Young International | 1,357 |
| Karyopharm Therapeutics | 325 |
| EDAP TMS | 307 |
| Cibus | 183 |
| Exagen | 179 |
| Theratechnologies | 103 |
| Assertio Holdings | 53 |
| Entera Bio | 18 |
CNTX News
- 6 weeks ago - Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 2 months ago - Context Therapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewsWire
- 2 months ago - Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 3 months ago - Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors - GlobeNewsWire
- 4 months ago - Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 5 months ago - Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations - GlobeNewsWire
- 5 months ago - Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline - Seeking Alpha
- 5 months ago - Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 - GlobeNewsWire